Anzeige
Mehr »
Freitag, 25.07.2025 - Börsentäglich über 12.000 News
Lizenz aktiviert - Kooperation fix: Diese Aktie will jetzt den Milliardenmarkt erobern!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von FierceBiotech

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
17.07.I-Mab buys Bridge Health for $3M-plus to strengthen pivot to CLDN18.2 bispecific
17.07.Novartis' B cell-depleting antibody fails to show promise in phase 2 dermatology study
16.07.Sarepta pivots to siRNA and lays off 500 staffers as Elevidys gets box warning
16.07.Otsuka inks $613M deal for Swedish biotech's autoimmune antibodies
16.07.Okyo sets sights on first approval in neuropathic eye pain after phase 2 win
16.07.Alphabet's SandboxAQ teams up with Swiss biotech to develop mRNA cancer vaccine
16.07.NIH fires exec amid probe into wife's role in $3.3M contract: report
16.07.Kezar sees hepatitis hold lifted, hints at resurrecting lupus program
16.07.Repare finds suitor for paused PKMYT1 inhibitor in current partner Debiopharm
16.07.AstraZeneca's AL amyloidosis drug fails to reduce mortality in phase 3 test
15.07.GSK telegraphs 'very limited number' of job cuts amid R&D investment spree
15.07.HHS terminates employees after Supreme Court allows reduction in force to proceed
15.07.Sellas' CDK9 inhibitor tied to 50% response rate in certain AML patients in phase 2 study
15.07.Sino Biopharm buys Merck's PD-1xVEGF bispecific partner LaNova for up to $951M
15.07.Hengrui's GLP-1/GIP agonist reports 18% weight loss in phase 3 trial, readies China push
15.07.Acumen taps JCR's blood-brain barrier tech for $555M Alzheimer's deal
14.07.China biotechs 'reshaping' US biopharma as outlicensing deals rise 11%: Jefferies report
14.07.Merck wades deeper into HIV PrEP waters dominated by Gilead with 2 new late-stage trials
14.07.Research non-profit to acquire embattled Essa in Xoma Royalty-backed deal
14.07.Takeda's narcolepsy blockbuster hopeful secures double phase 3 wins, teeing up FDA filing
14.07.AstraZeneca's $1.3B bet on CinCor's blood pressure med appears to pay off with phase 3 win
11.07.Relmada terminates license agreement for troubled phase 3 depression asset
11.07.Karyopharm lays off more workers as hunt for strategic alternatives turns up short
11.07.FDA rejects Capricor's DMD cell therapy, asks for more data
10.07.FDA releases 'initial batch' of more than 200 drug rejection letters